INTENSITY THERAPEUTICS INC (INTS) Stock Price & Overview
NASDAQ:INTS • US45828J2024
Current stock price
The current stock price of INTS is 5.5 USD. Today INTS is down by -1.79%. In the past month the price decreased by -25.88%. In the past year, price decreased by -88.36%.
INTS Key Statistics
- Market Cap
- 13.97M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.56
- Dividend Yield
- N/A
INTS Stock Performance
INTS Stock Chart
INTS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to INTS. When comparing the yearly performance of all stocks, INTS is a bad performer in the overall market: 97.64% of all stocks are doing better.
INTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INTS. The financial health of INTS is average, but there are quite some concerns on its profitability.
INTS Earnings
INTS Forecast & Estimates
12 analysts have analysed INTS and the average price target is 57.29 USD. This implies a price increase of 941.64% is expected in the next year compared to the current price of 5.5.
INTS Groups
Sector & Classification
INTS Financial Highlights
Over the last trailing twelve months INTS reported a non-GAAP Earnings per Share(EPS) of -11.56. The EPS increased by 60.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.31% | ||
| ROE | -97.73% | ||
| Debt/Equity | 0 |
INTS Ownership
INTS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About INTS
Company Profile
Intensity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Company Info
IPO: 2023-06-30
INTENSITY THERAPEUTICS INC
1 Enterprise Drive, Suite 430
Shelton CONNECTICUT US
Employees: 5
Phone: 12032217381
INTENSITY THERAPEUTICS INC / INTS FAQ
What does INTS do?
Intensity Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Can you provide the latest stock price for INTENSITY THERAPEUTICS INC?
The current stock price of INTS is 5.5 USD. The price decreased by -1.79% in the last trading session.
What is the dividend status of INTENSITY THERAPEUTICS INC?
INTS does not pay a dividend.
What is the ChartMill technical and fundamental rating of INTS stock?
INTS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of INTENSITY THERAPEUTICS INC (INTS) based on its PE ratio?
INTENSITY THERAPEUTICS INC (INTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.56).
Would investing in INTENSITY THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INTS.
What is the ownership structure of INTENSITY THERAPEUTICS INC (INTS)?
You can find the ownership structure of INTENSITY THERAPEUTICS INC (INTS) on the Ownership tab.